German market leader within a few years

Business development

M1 has a clear growth strategy within the established business model. Since the opening of our first location in Berlin in 2012, we have continuously developed. Today, M1 is the market leader in Germany and has started the international expansion. In the coming years we will open numerous new locations in Germany and roll out the successful their model internationally. We see great potential in practically every country in Western Europe and beyond. After all, the markets for cosmetic surgery are very fragmented and prices are too high.

In addition, we see potential in other areas of aesthetic and plastic medicine and, from a medical point of view, the demand for specialization. That, we want to take advantage of.


Latest news

| Investor News

M1 Kliniken AG announces that the sale of HAEMATO Pharm GmbH by its majority holding, HAEMATO AG (85%), to the PHOENIX group was successfully completed effective as of the end of January 31, 2026.

| Investor News

The Supervisory Board of M1 Kliniken AG has appointed Ms. Katharina Zimmnau to the Executive Board of M1 Kliniken AG with effect from 10. December 2025.

| Investor News

  • Group revenue: +6.7% to EUR 274.3 million (YTD Q3 2024: EUR 257.2 million)
  • EBITDA: +9% to EUR 28.2 million (YTD Q3 2024: EUR 25.9 million)
  • EBIT: +11% to EUR 24.5 million (YTD Q3 2024: EUR 22.1 million)
  • EBIT margin: 8.9% (YTD Q3 2024: 8.6%)
  • EBT: +10% to EUR 24.4 million (YTD Q3 2024: EUR 22.2 million)
  • Earnings per share: EUR 0.86 (YTD Q3 2024: EUR 0.77)

| Ad-hoc news

M1 Kliniken AG announces that its 85% subsidiary, HAEMATO AG, today signed an agreement for the sale of its wholly owned subsidiary HAEMATO Pharm GmbH to the PHOENIX group, one of Europe’s leading healthcare providers headquartered in Mannheim. The completion of the transaction remains subject to the customary antitrust approvals. The parties have agreed not to disclose the financial details of the transaction.

With this transaction, M1 Kliniken AG is consistently pursuing its strategic course to position itself as a globally leading, vertically integrated pure-play provider in the field of medical aesthetics.